Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second HLA-identical sibling transplants for leukemia recurrence.

M Mrsíc1, M M Horowitz, K Atkinson

  • 1International Bone Marrow Transplant Registry, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee 53226.

Bone Marrow Transplantation
|April 1, 1992
PubMed
Summary

Second transplants improve leukemia-free survival for patients relapsing more than six months after their initial HLA-identical sibling transplant, offering better outcomes than early relapses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.

Leukemia·2019
Same author

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Journal of internal medicine·2018
Same author

Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients.

Bone marrow transplantation·2018
Same author

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.

Biomolecular detection and quantification·2018
Same author

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Journal of internal medicine·2017

Area of Science:

  • Hematology
  • Transplantation Immunology

Background:

  • Relapse after hematopoietic stem cell transplantation (HSCT) necessitates further treatment.
  • Second HSCT is an option for relapsed patients, but outcomes vary.

Purpose of the Study:

  • To evaluate outcomes of second HLA-identical sibling HSCT in patients with leukemia.
  • To identify factors influencing survival and complications after second HSCT.

Main Methods:

  • Retrospective analysis of 114 patients undergoing second HLA-identical sibling HSCT for leukemia between 1978-1989.
  • Data collected on transplant interval, disease type, graft-versus-host disease (GVHD), mortality, relapse, and survival.

Main Results:

  • Two-year leukemia-free survival was 21%, with higher risks of interstitial pneumonia and hepatic veno-occlusive disease after second HSCT.

Related Experiment Videos

  • Patients relapsing >6 months before second HSCT had better leukemia-free survival (28%) than those relapsing <6 months (7%).
  • Favorable factors included chronic myelogenous leukemia, relapse >6 months post-first transplant, remission before second transplant, and good performance status.

    • Conclusions:

    • Second HLA-identical sibling HSCT can be effective, particularly for patients relapsing later.
    • Timing of relapse relative to the first transplant is a critical prognostic factor.
    • Careful patient selection and management are essential to optimize outcomes and mitigate risks.